Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 2 of 33 for:    saracatinib

Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis (SLAM-2)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2016 by Baylor College of Medicine
University of Cincinnati
Brigham and Women's Hospital
Stanford University
Loyola University
University of South Florida
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Tony Eissa, Baylor College of Medicine Identifier:
First received: March 31, 2016
Last updated: November 28, 2016
Last verified: November 2016
This study is being done to determine if there is a potential benefit of saracatinib in LAM subjects. Based on the information of this trial, additional clinical development trials will be needed. The study will also test the tolerability of 125 mg of saracatinib given once daily over a 9 month period.

Condition Intervention Phase
Pulmonary Lymphangioleiomyomatosis
Drug: saracatinib
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis

Resource links provided by NLM:

Further study details as provided by Baylor College of Medicine:

Primary Outcome Measures:
  • FEV1 [ Time Frame: 9 months ]

Secondary Outcome Measures:
  • Angiomyolipoma measured volumetrically on MRI [ Time Frame: 12 months ]
  • Lung Cyst size measured on chest CT [ Time Frame: 9 months ]
  • VEGF-D serum levels [ Time Frame: 12 months ]

Other Outcome Measures:
  • Pulmonary Function Testing [ Time Frame: 12 months ]

Estimated Enrollment: 28
Study Start Date: April 2016
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Saracatinib
Saracatinib will be given orally at a dose of 125 milligrams once daily for 9 months. Saracatinib is provided as a pink tablet.
Drug: saracatinib
Subjects will receive enough tablets for 90 days +/- 14 days at each visit. Subject will have visits every 90 days for drug accountability as well as safety and efficacy testing to include pulmonary function testing, laboratory testing to include liver and kidney profile, urine pregnancy testing at each visit, vital signs, physical examination - any medically significant changes from baseline visit will be recorded, all adverse events will be monitored until resolution.
Other Name: AZD0530

Detailed Description:

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in tuberous sclerosis complex 1 (TSC1) or TSC2 tumor suppressor genes. TSC is characterized by tumors in a wide range of tissues, seizures, mental retardation, autism, and organ failure. Lymphangioleiomyomatosis (LAM), the major pulmonary manifestation in women with TSC, is a progressive lung disease characterized by infiltration of atypical smooth muscle like cells (TSC-/- LAM cells) and formation of parenchymal cysts. Sporadic LAM can develop in women who do not meet the criteria for the diagnosis of TSC, owing to somatic mutations in the TSC2 gene.

The long term goal of this research is to devise novel therapeutic strategies for patients with LAM. The observed behavior of LAM cells with respect to their infiltrative growth pattern, metastatic potential, and altered cell differentiation is reminiscent of cells undergoing epithelial-mesenchymal transition (EMT). Src kinases are key regulators of cellular proliferation, motility, invasiveness and EMT. Recent results have shown that autophagy promotes degradation of active Src. Thereby, decreased autophagy due to mTOR activation known to occur in LAM cells, may play a significant role in accumulation of active Src in these cells. Src suppresses transcription of E-cadherin by upregulating its transcriptional repressors. The preliminary data reveal an increase in active Src in lung tissues of patients with LAM as well as in cultured TSC2-/- cells. Further, in TSC2-/- cells, E-cadherin is considerably reduced and does not localize to the plasma membrane, as it does in wild-type cells.

The focus of this study is to examine if Src inhibition represents a potential therapeutic strategy in LAM. It is proposed that Src activation in TSC2-/- cells results in the reduction of E-cadherin, loss of cell-cell adhesion and elevation of oncogenic and metastatic potential of these cells. The increased Src activity in TSC2-/- cells is likely caused by inhibition of autophagy associated with hyper-activation of mTOR. Therefore, the use of Src inhibitors may lead to a reduction in tumor growth and prevent dissemination of TSC2-/- cells. In this study, the investigators will evaluate the safety and efficacy of Src inhibition in subjects with LAM.

A number of inhibitors of Src are now in clinical trials in patients with a range of different tumors. Dasatinib, an oral adenosine triphosphate (ATP)-competitive Src inhibitor, is now approved for clinical use in patients with chronic myeloid leukemia or acute lymphoblastic leukemia. However, dasatinib has wider 'off target' inhibitory activity than saracatinib including potent activity against Abl, ephrin receptor kinases, platelet-derived growth factor receptor and c-KIT (type of receptor tyrosine kinase and a type of tumor marker. Also called CD117 and stem cell factor receptor.) In contrast, saracatinib has a >10-fold preference for Src over Abl kinases and has very little activity against other tyrosine and serine/threonine kinases. Saracatinib has been already characterized in multiple clinical trials in terms of safety and pharmacokinetics.

The investigators have conducted a Phase1b study to test the safety of various doses of Saracatinib in LAM subjects. The purpose of the Phase1b trial was to determine the optimal dose in terms of safety and tolerability in LAM population. Three escalating doses of saracatinib; 50, 125 and 175 mg were studied. Saracatinib was given orally once a day. Overall, subjects tolerated Saracatinib well. The investigators chose the dose of 125 mg to conduct further testing of both safety and efficacy in this Phase 2a trial.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female patients. It should be noted that LAM occurs almost exclusively in women.
  • 18 to 65 years of age.
  • All patients must have a diagnosis of LAM as defined by compatible cystic changes on chest computed tomography (CT) and one of the following:
  • Open lung, transbronchial or thoracic needle biopsy consistent with LAM
  • Open or needle abdominal biopsy findings consistent with LAM
  • Clinical findings of tuberous scleroma complex (TSC), renal angiomyolipoma, cystic abdominal lymphangiomas, or history of chylous effusion in the chest or abdomen
  • Serum vascular endothelial growth factor D (VEGF-D) > 800 pg/ml
  • Subjects must have had a recent reduction in forced expiratory volume at 1-second (FEV1) of > 50ml/year, as shown by at least two pulmonary function testing (PFT) measured at least 6 months apart in the last 24 months prior to enrolling study.

Exclusion Criteria:

  • Current infection.
  • Major surgery within the past 2 months
  • Advanced hematologic, renal, hepatic, non-LAM lung disease or metabolic diseases; or BMI of >35
  • The use of another investigational drug within 30 days
  • The use of mTOR (mammalian target of rapamycin) inhibitors within 30 days
  • Previous lung transplantation.
  • Inability to attend scheduled clinic visits
  • Inability to give informed consent
  • Inability to perform pulmonary function testing
  • History of malignancy in the past two years, other than squamous or basal cell skin cancer or status post successful excision or treatment.
  • Nursing mothers
  • Current or planned pregnancy.
  • Not using adequate contraception (in woman of childbearing potential).
  • Significant clinical change in health in the past 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02737202

Contact: Caryn O Pope 7132189918
Contact: Patricia Lukaszewski 713-798-8959

United States, California
Stanford University Recruiting
Stanford, California, United States, 94305
Contact: Susan Jacobs, RN MS    650-725-8083   
Principal Investigator: Stephen Ruoss, MD         
United States, Illinois
Loyola Medical Center Not yet recruiting
Chicago, Illinois, United States, 90153
Contact: Elizabeth Kirwan, RN    708-216-2057   
Principal Investigator: Daniel Dilling, MD         
United States, Maryland
Laboratory of Translational Research NHLBI Not yet recruiting
Bethesda, Maryland, United States, 20814
Contact: Mary Haughey, RN    301-496-3632   
Principal Investigator: Joel Moss, MD         
United States, Massachusetts
Brigham and Women's Hospital - Boston Not yet recruiting
Boston, Massachusetts, United States, 02115
Contact: Souheil Y El-Chemaly, MD    617-355-9049    SEL-CHEMALY@PARTNERS.ORG   
Principal Investigator: Souheil Y El-Chemaly, MD         
United States, Ohio
University of Cincinnati Not yet recruiting
Cincinnati, Ohio, United States, 45267
Contact: Tammy Roads    513-558-2148   
Principal Investigator: Frank X McCormack, MD         
United States, Texas
Baylor College of Medicine - Ben Taub General Hospital Recruiting
Houston, Texas, United States, 77030
Contact: Caryn O Pope    713-873-2471   
Principal Investigator: Nicola A Hanania, MD         
Sponsors and Collaborators
Baylor College of Medicine
University of Cincinnati
Brigham and Women's Hospital
Stanford University
Loyola University
University of South Florida
National Institutes of Health (NIH)
Study Chair: Tony Eissa, MD Baylor College of Medicine
Principal Investigator: Nicola A Hanania, MD Ben Taub Hospital
Principal Investigator: Souheil Y El-Chemaly, MD Brigham and Women's Hospital - Boston
Principal Investigator: Francis X McCormack, MD University of Cincinnati
Principal Investigator: Daniel Dilling, MD Loyola University
Principal Investigator: Stephen Ruoss, MD Stanford University
Principal Investigator: Joel Moss, MD Laboratory of Translational Research - NHLBI
  More Information


Responsible Party: Tony Eissa, Principal Investigator, Baylor College of Medicine Identifier: NCT02737202     History of Changes
Other Study ID Numbers: SLAM 7602
4UH3TR000961-02 ( US NIH Grant/Contract Award Number )
Study First Received: March 31, 2016
Last Updated: November 28, 2016
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Baylor College of Medicine:

Additional relevant MeSH terms:
Lymphatic Vessel Tumors
Neoplasms by Histologic Type
Perivascular Epithelioid Cell Neoplasms
Neoplasms, Connective and Soft Tissue
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017